- Home
- KWE vs QLGN Comparison
KWE vs QLGN Comparison
Compare KWE & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KWE
- QLGN
- Stock Information
- Founded
- KWE 2017
- QLGN 1996
- Country
- KWE Canada
- QLGN United States
- Employees
- KWE N/A
- QLGN N/A
- Industry
- KWE
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- KWE
- QLGN Health Care
- Exchange
- KWE Nasdaq
- QLGN Nasdaq
- Market Cap
- KWE 2.3M
- QLGN 2.2M
- IPO Year
- KWE N/A
- QLGN N/A
- Fundamental
- Price
- KWE $5.14
- QLGN $3.87
- Analyst Decision
- KWE
- QLGN
- Analyst Count
- KWE 0
- QLGN 0
- Target Price
- KWE N/A
- QLGN N/A
- AVG Volume (30 Days)
- KWE 559.4K
- QLGN 44.7K
- Earning Date
- KWE 05-23-2025
- QLGN 07-01-2025
- Dividend Yield
- KWE N/A
- QLGN N/A
- EPS Growth
- KWE N/A
- QLGN N/A
- EPS
- KWE N/A
- QLGN N/A
- Revenue
- KWE $1,572,738.00
- QLGN N/A
- Revenue This Year
- KWE N/A
- QLGN N/A
- Revenue Next Year
- KWE N/A
- QLGN N/A
- P/E Ratio
- KWE N/A
- QLGN N/A
- Revenue Growth
- KWE 116.30
- QLGN N/A
- 52 Week Low
- KWE $0.22
- QLGN $2.85
- 52 Week High
- KWE $243.60
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- KWE 47.83
- QLGN 61.76
- Support Level
- KWE $5.15
- QLGN $3.40
- Resistance Level
- KWE $7.10
- QLGN $3.95
- Average True Range (ATR)
- KWE 0.73
- QLGN 0.26
- MACD
- KWE 0.10
- QLGN 0.03
- Stochastic Oscillator
- KWE 31.15
- QLGN 69.82
About KWE KWESST Micro Systems Inc.
KWESST Micro Systems Inc develops and commercializes next-generation tactical systems. The company offers breakthrough technology in lethal and non-lethal systems with broad application, including law enforcement and personal defence, modernized digitization of tactical forces for shared situational awareness and targeting, and counter-measures against threats such as drones, lasers and electronic detection.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.